跳至主要内容

Development Trend of Medicinal Chemistry

The progress of medicinal chemistry and a large number of new drugs listed in the late 20th century, mainly summarized as two reasons: 1) Life sciences, such as structural biology, molecular biology, molecular genetics, genetics and biotechnology, to provide theoretical basis and technical support for the discovery of new drugs; 2) the rapid development of scientific information such as the establishment of bioinformatics, the development of biochips, the application of various information kiosks and information technology, can easily retrieve and search the required literature and the research level and efficiency greatly improved.


In order to strive for the international market, pharmaceutical companies invested a lot of money for new drug research and development; new varieties of drugs continue to promote the rapid development of the pharmaceutical industry.

We will usher in the new century of knowledge economy in the near future. Knowledge innovation, technological innovation, scientific and technological progress and economic development will be the main task facing life science and information science will be increasingly developed to become an active area of the next century, which for disease prevention and treatment, new drug research provides an important foundation.

Medicinal chemistry, biology and biotechnology connected closely is still the future development trend.

Medicilon’s chemistry department possesses advanced synthetic medicinal chemistry skills and an excellent record-tracking system to progress programs and generate preclinical candidates. We can rapidly transform your drug discovery program from hit screening to SAR-driven medicinal chemistry in an efficient and cost effective manner. We use state-of-the-art parallel synthesis and purification technology to prepare high-quality compound libraries. Our chemists have extensive experiences in working with clients on hit to lead and lead optimization for candidate’s programs, and in converting medicinal synthetic routes of compounds into processes that make multi-kilogram quantities to support animal studies within a restricted time frame.

Medicinal Chemistry

We utilize medicinal chemistry efficiently and cost-effectively to progress our client’s drug discovery projects to candidate nomination, preclinical development, and IND.

> Hit to lead and/or lead optimization
> Rational Drug Design
> Computer Aided Drug Design (CADD)
> Structure Activity Relationship (SAR) Campaign
> Final Lead Optimization and Candidate Nomination
> Process Development of Preclinical Candidate

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%.

Well-designed and well-validated analytical methodology is critical to data integrity and central to our approach. We work closely with clients to ensure that our methodology will yield accurate results. Meanwhile, our precise quality systems ensure that all the facilities, equipment, methods, practices, records, and controls are tightly compliant with our regulations, study protocols, and standard operating procedures.

Contact Us 

Email : marketing@medicilon.com

Tel : +44 1223 981 792 (Europe)

+82 (0)70-8269-5849 (South Korea)

08044216898 (Japan)

+86 021 58591500 (China)

Website: https://www.medicilon.com

评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...